Fulgent Genetics Analyst Ratings
Fulgent Genetics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/16/2023 | 11.29% | Piper Sandler | $37 → $28 | Maintains | Neutral |
| 03/02/2023 | 78.86% | Credit Suisse | $50 → $45 | Maintains | Outperform |
| 12/08/2022 | 58.98% | Piper Sandler | $65 → $40 | Downgrades | Overweight → Neutral |
| 11/18/2022 | 78.86% | Raymond James | → $45 | Initiates Coverage On | → Outperform |
| 11/14/2022 | 98.73% | Credit Suisse | $65 → $50 | Maintains | Outperform |
| 11/14/2022 | 158.35% | Piper Sandler | $70 → $65 | Maintains | Overweight |
| 08/25/2022 | 158.35% | Credit Suisse | → $65 | Initiates Coverage On | → Outperform |
| 05/16/2022 | 178.22% | Piper Sandler | $85 → $70 | Maintains | Overweight |
| 01/25/2022 | 396.82% | Oppenheimer | $141 → $125 | Maintains | Outperform |
| 08/10/2021 | 158.35% | Credit Suisse | $55 → $65 | Maintains | Underperform |
| 03/05/2021 | 456.44% | Piper Sandler | $135 → $140 | Maintains | Overweight |
| 02/01/2021 | 416.69% | Oppenheimer | $75 → $130 | Maintains | Outperform |
| 01/08/2021 | — | Credit Suisse | Downgrades | Neutral → Underperform | |
| 11/24/2020 | — | BTIG | Downgrades | Buy → Neutral | |
| 09/25/2020 | 66.93% | Credit Suisse | $13 → $42 | Maintains | Neutral |
| 08/20/2020 | 198.09% | Oppenheimer | → $75 | Initiates Coverage On | → Outperform |
| 07/27/2020 | 23.21% | Piper Sandler | $21 → $31 | Maintains | Overweight |
| 06/17/2020 | -16.53% | Piper Sandler | $18 → $21 | Maintains | Overweight |
| 05/29/2020 | -20.51% | BTIG | → $20 | Initiates Coverage On | → Buy |
| 05/05/2020 | -56.28% | Credit Suisse | $12 → $11 | Maintains | Neutral |
| 11/05/2019 | -51.11% | Piper Sandler | $9.5 → $12.3 | Upgrades | Neutral → Overweight |
| 04/26/2019 | — | Credit Suisse | Downgrades | Outperform → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 10/16/2023 | 11.29% | 派珀·桑德勒 | $37→$28 | 维护 | 中性 |
| 03/02/2023 | 78.86% | 瑞士信贷 | $50→$45 | 维护 | 跑赢大盘 |
| 12/08/2022 | 58.98% | 派珀·桑德勒 | $65→$40 | 评级下调 | 超重→中性 |
| 2022年11月18日 | 78.86% | 雷蒙德·詹姆斯 | →$45 | 开始承保 | →跑赢大盘 |
| 2022年11月14日 | 98.73% | 瑞士信贷 | $65→$50 | 维护 | 跑赢大盘 |
| 2022年11月14日 | 158.35% | 派珀·桑德勒 | $70→$65 | 维护 | 超重 |
| 2022年08月25日 | 158.35% | 瑞士信贷 | →$65 | 开始承保 | →跑赢大盘 |
| 05/16/2022 | 178.22% | 派珀·桑德勒 | $85→$70 | 维护 | 超重 |
| 01/25/2022 | 396.82% | 奥本海默 | $141→$125 | 维护 | 跑赢大盘 |
| 2021/08/10 | 158.35% | 瑞士信贷 | $55→$65 | 维护 | 表现不佳 |
| 03/05/2021 | 456.44% | 派珀·桑德勒 | $135→$140 | 维护 | 超重 |
| 02/01/2021 | 416.69% | 奥本海默 | $75→$130 | 维护 | 跑赢大盘 |
| 01/08/2021 | - | 瑞士信贷 | 评级下调 | 中性→表现不佳 | |
| 11/24/2020 | - | BTIG | 评级下调 | 购买→中性 | |
| 09/25/2020 | 66.93% | 瑞士信贷 | $13→$42 | 维护 | 中性 |
| 08/20/2020 | 198.09% | 奥本海默 | →$75 | 开始承保 | →跑赢大盘 |
| 07/27/2020 | 23.21% | 派珀·桑德勒 | $21→$31 | 维护 | 超重 |
| 06/17/2020 | -16.53% | 派珀·桑德勒 | $18→$21 | 维护 | 超重 |
| 05/29/2020 | -20.51% | BTIG | →$20 | 开始承保 | →购买 |
| 05/05/2020 | -56.28% | 瑞士信贷 | $12→$11 | 维护 | 中性 |
| 2019年11月05日 | -51.11% | 派珀·桑德勒 | $9.5→$12.3 | 升级 | 中性→超重 |
| 2019年04月26日 | - | 瑞士信贷 | 评级下调 | 跑赢→中性 |
What is the target price for Fulgent Genetics (FLGT)?
Fulgent Genetics(FLGT)的目标价是多少？
The latest price target for Fulgent Genetics (NASDAQ: FLGT) was reported by Piper Sandler on October 16, 2023. The analyst firm set a price target for $28.00 expecting FLGT to rise to within 12 months (a possible 11.29% upside). 6 analyst firms have reported ratings in the last year.
派珀·桑德勒于2023年10月16日报道了富金特遗传公司(纳斯达克股票代码：FLGT)的最新目标价。这家分析公司将目标价定为28.00美元，预计FLGT将在12个月内上涨(可能上涨11.29%)。6家分析公司在过去一年公布了评级。
What is the most recent analyst rating for Fulgent Genetics (FLGT)?
富力遗传(Fulgent Genetics)最新的分析师评级是多少？
The latest analyst rating for Fulgent Genetics (NASDAQ: FLGT) was provided by Piper Sandler, and Fulgent Genetics maintained their neutral rating.
纳斯达克(Sequoia Capital：FLGT)的最新分析师评级由派珀·桑德勒提供，富尔金特遗传公司维持中性评级。
When is the next analyst rating going to be posted or updated for Fulgent Genetics (FLGT)?
Fulgent Genetics(FLGT)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Fulgent Genetics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Fulgent Genetics was filed on October 16, 2023 so you should expect the next rating to be made available sometime around October 16, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Fulgent Genetics的高管和客户交谈，以及收听收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Fulgent Genetics的上一次评级是在2023年10月16日提交的，所以你应该预计下一次评级将在2024年10月16日左右的某个时候公布。
Is the Analyst Rating Fulgent Genetics (FLGT) correct?
分析师对Fulgent Genetics(FLGT)的评级正确吗？
While ratings are subjective and will change, the latest Fulgent Genetics (FLGT) rating was a maintained with a price target of $37.00 to $28.00. The current price Fulgent Genetics (FLGT) is trading at is $25.16, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Fulgent Genetics(FLGT)评级保持不变，目标价在37.00美元至28.00美元之间。富尔金特基因公司目前的股价为25.16美元，超出了分析师的预测范围。